Staff Members - Benha University
Secretion of glucagon- like peptide-1 (GLP-1) in type 2 diabetic patients: Study of its relation to glucose lowering effect of dipeptidyl peptidase IV (DPP-IV) inhibitors.
Nature and Science • 2015
Publication Information
Authors
Rizk Sayad Rizk Sarhan, Atef Ahmed Ebraheem, Mohammed Shawky El-Sayed, Roshdy Khalf Allah, Khaled Mostafa Belal
Keywords
glucagon- like peptide-1, Type2 DM, dipeptidyl peptidase IV (DPP-IV) inhibitors,GLP-1 level, incretin
hormone, incretin based therapy
Journal
Nature and Science
Publisher
Rizk Sayad Rizk Sarhan
Volume
13(6)
Issue
ISSN: 1545- 0740)
Pages
75-87
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Abstract: Background: (1) Th aims of this study are to investigate the glycemic efficy and predictive parameters of
DPP IV inhibitors therapy in Egyptian subjects with type 2 diabetes. (2) Investigate the level and the determinants
that affect the secretion of glucagone like peptide-1(GLP-1) in Type2 diabetic patients. Subjects and Methods:
This study was conducted on 70 type 2 diabetes patients【35 males & 35 females】 under known antidiabetic drugs,
Their ages range was (30-63y) and average mean (46.31±10.75 y), as well as 20 apparently healthy subject's
volunteers served as control 【12 males & 8 females】 with age range (28-50y) and SD (37.40±5.04 y). DPP-4
inhibitors were added to every patient after the start of the study. The patients were followed at monthly interval for
3 months after the beginning of DPP-4 inhibitors therapy. Results: GLP-1 levels were significantly decreased in
DM subjects compared to controls (261.33± 9.37 vs.75.48 ± 20.81pg/mL, p
DPP IV inhibitors therapy in Egyptian subjects with type 2 diabetes. (2) Investigate the level and the determinants
that affect the secretion of glucagone like peptide-1(GLP-1) in Type2 diabetic patients. Subjects and Methods:
This study was conducted on 70 type 2 diabetes patients【35 males & 35 females】 under known antidiabetic drugs,
Their ages range was (30-63y) and average mean (46.31±10.75 y), as well as 20 apparently healthy subject's
volunteers served as control 【12 males & 8 females】 with age range (28-50y) and SD (37.40±5.04 y). DPP-4
inhibitors were added to every patient after the start of the study. The patients were followed at monthly interval for
3 months after the beginning of DPP-4 inhibitors therapy. Results: GLP-1 levels were significantly decreased in
DM subjects compared to controls (261.33± 9.37 vs.75.48 ± 20.81pg/mL, p